SOUTH SAN FRANCISCO, Calif., Dec. 3, 2012 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (FivePrime), a clinical-stage company discovering and developing innovative antibody and protein therapeutics, announced today that Julie Hambleton, MD, has joined FivePrime as Senior Vice President and Chief Medical Officer, bringing over 25 years of clinical, academic and drug development experience to FivePrime.
"Dr. Hambleton is a premier drug developer and leader in the industry and we are delighted that she has joined FivePrime," said Lewis T. "Rusty" Williams, MD, PhD, Founder, President and Chief Executive Officer of FivePrime. "Dr. Hambleton's extensive pharmaceutical development track record and the breadth and depth of her expertise will strengthen our executive team. We expect Dr. Hambleton will have a significant impact on FivePrime's continued evolution as a development-stage company."
Prior to joining FivePrime, Dr. Hambleton served as Vice President, Clinical Development, at Clovis Oncology, Inc. where she oversaw the clinical development of CO-1686, a mutant selective epidermal growth factor receptor (EGFR) inhibitor targeting non-small cell lung cancer, and rucaparib, a poly ADP-ribose polymerase (PARP) inhibitor initially targeting ovarian and breast cancers. From 2003 to 2010, Dr. Hambleton served at Genentech, Inc. in positions of increasing responsibility, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting seven phase 3 trials of Genentech's Avastin® (bevacizumab) antibody in different indications.
During her tenure at both Clovis and Genentech, Dr. Hambleton played a significant role in drug development programs for numerous molecules at all stages of development—from pre-clinical through phase 4 and other post-marketing studies—involving more than two dozen clinical trials. She also brings to FivePrime extensive experience working with regulatory agencies to advance the development of new molecules, including with the U.S. Food and Drug Administration and the European Medicines Agency (EMA), and has played a significant role in filings of investigational new drug (IND) applications, biologics license applications (BLAs) and special protocol assessments (SPAs).
Prior to joining industry, Dr. Hambleton served for 10 years in academic positions in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF), most recently as Associate Professor of Clinical Medicine. Prior to her academic positions, she completed seven years of post-graduate training at UCSF, where she served as Chief Medical Resident and a Fellow in the Division of Hematology/Oncology.
Dr. Hambleton received a B.S. degree from Duke University, and an M.D. degree from Case Western Reserve University School of Medicine. She is Board-certified in Hematology and Internal Medicine.
Five Prime Therapeutics, Inc. is a clinical-stage, privately held, biotechnology company discovering and developing innovative antibody and protein therapeutics. Using its integrated discovery platform, FivePrime is building a strong pipeline of oncology and immunology drug candidates. FivePrime mines its comprehensive library of secreted and extracellular human proteins to screen for medically relevant new therapeutic proteins and antibody targets. FivePrime has entered into a collaboration agreement to develop and commercialize its lead product, FP-1039, with Human Genome Sciences, Inc. (which GlaxoSmithKline has acquired) in the United States, Canada and the EU. FivePrime has also established significant collaborations for the discovery of innovative biologics in specific therapeutic areas with several leading pharmaceutical companies, including Pfizer, Centocor and GlaxoSmithKline. For more information about FivePrime, please visit FivePrime's web site at www.fiveprime.com.
The Five Prime Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8029
CONTACT: Amy Kendall Corporate Communications 415-365-5776 email@example.com
Source: FivePrime Therapeutics, Inc.